StocksMedium•5 November 2026•
1 min read
Genmab Revenue Grows 22% in First Nine Months of 2026
Key Facts
1Genmab reported a 22% increase in revenue for the first nine months of 2026.
2The revenue growth was driven by the delivery of the company's late-stage drug pipeline.
Genmab reported a 22% increase in revenue for the first nine months of 2026. According to investing.com, the revenue growth was driven by the delivery and performance of the company's late-stage drug pipeline.
GMAB closed at $55.12 on November 4, 2026. During that session, the stock traded between a low of $53.76 and a high of $56.20.